Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01560507 · ClinicalTrials.gov registry record · Phase 2
Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants
A Phase 2 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT01560507: Clinical Trial Phase 2 study, sponsored by Duke University.
NCT01560507 is a Phase 2 study that was terminated before completion, run by Duke University. The registered enrollment target is 19 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01560507, a Phase 2 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to ascertain: 1) the rate of smoking cessation obtained using an adaptive treatment algorithm developed in previous clinical trials, in order to calculate cost-effectiveness of the treatment; 2) the relationship between genotype and response to cigarette smoking cessation treatment.
Primary Outcome
Study was terminated early due to difficulties with enrollment. No outcome measures were assessed.
Interventions
- DRUG varenicline (Chantix)
- DRUG bupropion (Zyban)
- DRUG nicotine patches
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Why NCT01560507 stopped before completion
NCT01560507 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 3 interventions - of which varenicline (Chantix) is the first listed.
NCT01560507 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01560507 about?
NCT01560507 is a clinical study titled "Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants". The purpose of this study is to ascertain: 1) the rate of smoking cessation obtained using an adaptive treatment algorithm developed in previous clinical trials, in order to calculate cost-effectiveness of the treatment; 2) the relationship between genotype and response to cigarette smoking cessatio...
What is the current status of trial NCT01560507?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2012-05. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01560507?
The interventions under investigation include: varenicline (Chantix) (DRUG), bupropion (Zyban) (DRUG), nicotine patches (DRUG).
Who is sponsoring clinical trial NCT01560507?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01560507's enrollment target sits among peer trials
19 1894th of 2000 higher than 103 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia